UNSPSC 51271801: Aptocaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08K838NNTE. European Medicines Agency schedules Aptocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05549MIG. Aptocaine generally arises in the molecular formula C14H20N2O.

The term APTOCAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) APTOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule aptocaine under HS 29339990 and SITC 51577. As of Q4 2014, APTOCAINE remains the US FDA Preferred Term for this commodity. Aptocaine bears US NLM identifiers UMLS ID C0052238 and NCI Concept Code C72172. SMILES: O=C(NC1C(CCCC1)C)C(N1CCCC1)C.

UNSPSC 51271801 Aptocaine is a Commodity code for local anesthetic pharmaceuticals, but recent state and local procurement activity shows minimal direct sourcing under this specific product code. The single identified opportunity—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026—casts a wide net across pharmaceutical classes rather than targeting aptocaine or related local anesthetics as a line item. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and extending to participating jurisdictions including Oregon, seeks manufacturers to supply comprehensive pricing across identified pharmaceutical products with specific National Drug Codes (NDC), though the actual product list is not detailed in available documentation. Vendors must certify compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements; maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with chargeback systems in place; and carry commercial general liability insurance of $5,000,000 per occurrence. The RFP does not identify set-aside designations or restrictions by business classification.

The MMCAP RFP with response deadline March 26, 2026, and contract effectiveness July 1, 2026, represents the primary recent activity visible under this code. Geographic scope spans Minnesota and Oregon at minimum within the MMCAP cooperative framework, with potential reach to other participating states. Evaluation weighs price competitiveness most heavily (75 percent), followed by fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). The contract term is two years for new vendors with optional extensions at MMCAP's discretion. No specific dollar values or product-quantity breakdowns for aptocaine are disclosed. State and local procurement activity under this code appears thin relative to broader pharmaceutical cooperative purchasing vehicles; firms pursuing local anesthetic supply should evaluate whether this specific code drives their target opportunities or whether higher-tier pharmaceutical family and class codes (UNSPSC 51270000 or 51271800-level) better capture current state and local demand.